Mager DE - Search Results

1

Physiologically based pharmacokinetic model for composite nanodevices: effect of charge and size on in vivo disposition.

Mager DE, Mody V, Xu C, Forrest A, Lesniak WG, Nigavekar SS, Kariapper MT, Minc L, Khan MK, Balogh LP. Mager DE, et al. Pharm Res. 2012 Sep;29(9):2534-42. doi: 10.1007/s11095-012-0784-7. Epub 2012 Jun 12. Pharm Res. 2012. PMID: 22688900

2

Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man.

Mager DE, Jusko WJ. Mager DE, et al. J Pharm Sci. 2002 Nov;91(11):2441-51. doi: 10.1002/jps.10231. J Pharm Sci. 2002. PMID: 12379930

3

Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans.

Mager DE, Jusko WJ. Mager DE, et al. Pharm Res. 2002 Oct;19(10):1537-43. doi: 10.1023/a:1020468902694. Pharm Res. 2002. PMID: 12425473

4

Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man.

Levy G, Mager DE, Cheung WK, Jusko WJ. Levy G, et al. Among authors: mager de. J Pharm Sci. 2003 May;92(5):985-94. doi: 10.1002/jps.10345. J Pharm Sci. 2003. PMID: 12712418

5

Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data.

Wyska E, Mager DE, Krzyzanski W. Wyska E, et al. Among authors: mager de. J Pharm Sci. 2003 Jul;92(7):1438-54. doi: 10.1002/jps.10407. J Pharm Sci. 2003. PMID: 12820148

6

Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys.

Mager DE, Neuteboom B, Jusko WJ. Mager DE, et al. Pharm Res. 2005 Jan;22(1):58-61. doi: 10.1007/s11095-004-9009-z. Pharm Res. 2005. PMID: 15771230

7

Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Mager DE, Krzyzanski W. Mager DE, et al. Pharm Res. 2005 Oct;22(10):1589-96. doi: 10.1007/s11095-005-6650-0. Epub 2005 Sep 22. Pharm Res. 2005. PMID: 16180117

8

Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: modeling interoccasion pharmacodynamic variability.

Hong Y, Mager DE, Blum RA, Jusko WJ. Hong Y, et al. Among authors: mager de. Pharm Res. 2007 Jun;24(6):1088-97. doi: 10.1007/s11095-006-9232-x. Epub 2007 Mar 24. Pharm Res. 2007. PMID: 17385022 Free PMC article. Clinical Trial.

9

Quantitative structure–property relationships of camptothecins in humans.

Xu C, Barchet TM, Mager DE. Xu C, et al. Among authors: mager de. Cancer Chemother Pharmacol. 2010 Jan;65(2):325-33. doi: 10.1007/s00280-009-1037-2. Cancer Chemother Pharmacol. 2010. PMID: 19488755

10

Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.

Kagan L, Abraham AK, Harrold JM, Mager DE. Kagan L, et al. Among authors: mager de. Pharm Res. 2010 May;27(5):920-32. doi: 10.1007/s11095-010-0098-6. Epub 2010 Mar 16. Pharm Res. 2010. PMID: 20232116 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

187 results

Search Page

Filters